Veronica Russell

Veronica Russell

Auto-generated profile, based on publicly available information

Veronica Russell

Duke University 2 , Durham, North Carolina

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
EBEmmanuela N. Bonglack
Emmanuela N. Bonglack
JMJoshua E. Messinger
Joshua E. Messinger
JCJana M. Cable
Jana M. Cable
JCJames Ch’nG
James Ch’nG
KPK. Mark Parnell
K. Mark Parnell
MLMicah Luftig
Micah Luftig
Epstein–Barr virus (EBV) is a ubiquitous herpesvirus that typically causes asymptomatic infection but can promote B lymphoid tumors in the immune suppressed. In vitro, EBV infection of primary B cells stimulates glycolysis during immortalization into lymphoblastoid cell lines (LCLs). Lactate export during glycolysis is crucial for continued proliferation of many cancer cells—part of a phenomenon known as the “Warburg effect”— and is mediated by monocarboxylate transporters (MCTs). However, the role of MCTs has yet to be studied in EBV-associated malignancies, which display Warburg-like metabolism in vitro. Here, we show that EBV infection of B lymphocytes directly promotes temporal induction of MCT1 and MCT4 through the viral proteins EBNA2 and LMP1, respectively. Functionally, MCT1 was required for early B cell proliferation, and MCT4 up-regulation promoted acquired resistance to MCT1 antagonism in LCLs. However, dual MCT1/4 inhibition led to LCL growth arrest and lactate buildup. Metabolic profiling in LCLs revealed significantly reduced oxygen consumption rates (OCRs) and NAD+/NADH ratios, contrary to previous observations of increased OCR and unaltered NAD+/NADH ratios in MCT1/4-inhibited cancer cells. Furthermore, U-13C6–glucose labeling of MCT1/4-inhibited LCLs revealed depleted glutathione pools that correlated with elevated reactive oxygen species. Finally, we found that dual MCT1/4 inhibition also sensitized LCLs to killing by the electron transport chain complex I inhibitors phenformin and metformin. These findings were extended to viral lymphomas associated with EBV and the related gammaherpesvirus KSHV, pointing at a therapeutic approach for targeting both viral lymphomas. Significance Epstein–Barr virus (EBV) infects virtually every human by adulthood with limited symptoms. However, in the context of immune suppression, EBV can cause lymphomas. EBV-associated lymphomas have poor prognoses and limited treatment options, highlighting a need to better understand EBV-mediated tumorigenesis. One common feature of viral replication and cancer is dysregulation of metabolism. Indeed, EBV dramatically reprograms host cell metabolism, up-regulating both oxidative phosphorylation and glycolysis. In this report, we identify metabolic vulnerabilities of EBV-infected primary human B cells, EBV-positive lymphomas, and lymphomas caused by the related oncogenic herpesvirus, KSHV. Pharmacological inhibition of lactate export suppressed these lymphomas and rendered them hypersensitive to metformin and phenformin. These findings together with our mechanistic studies outline a therapeutic strategy for viral lymphomas.

10 November 2021 in iScience
Verified
Journal Article
Open access
RGRia Goswami
Ria Goswami
VRVeronica S. Russell
Veronica S. Russell
JTJoshua J. Tu
Joshua J. Tu
CTCharlene Thomas
Charlene Thomas
PHPhilip Hughes
Philip Hughes
SPSallie Permar
Sallie Permar
Currently available SARS-CoV-2 therapeutics are targeted toward moderately to severely ill patients and require intravenous infusions, with limited options for exposed or infected patients with no or mild symptoms. Although vaccines have demonstrated protective efficacy, vaccine hesitancy and logistical distribution challenges will delay their ability to end the pandemic. Hence, there is a need for rapidly translatable, easy-to-administer-therapeutics that can prevent SARS-CoV-2 disease progression, when administered in the early stages of infection. We demonstrate that an orally bioavailable Hsp90 inhibitor, SNX-5422, currently in clinical trials as an anti-cancer therapeutic, inhibits SARS-CoV-2 replication in vitro at a high selectivity index. SNX-5422 treatment of human primary airway epithelial cells dampened expression of inflammatory pathways previously associated with poor SARS-CoV-2 disease outcomes. In addition, SNX-5422 interrupted expression of host factors demonstrated to be crucial for SARS-CoV-2 replication. Development of SNX-5422 as SARS-CoV-2-early-therapy will dampen disease severity, resulting in better clinical outcomes and reduced hospitalizations.

30 October 2026
Verified
Other
Open access
SYSheren Younes
Sheren Younes
FCFadzai Chinyengetere
Fadzai Chinyengetere
VRVeronica Russell
Veronica Russell
DTDevang Thakkar
Devang Thakkar
EMEmily F. Mason
Emily F. Mason
YNYasodha Natkunam
Yasodha Natkunam
Baseline clinical and demographic data of 23 patients with RDD.

30 October 2026
Verified
Other
Open access
SYSheren Younes
Sheren Younes
FCFadzai Chinyengetere
Fadzai Chinyengetere
VRVeronica Russell
Veronica Russell
DTDevang Thakkar
Devang Thakkar
EMEmily F. Mason
Emily F. Mason
YNYasodha Natkunam
Yasodha Natkunam
Differential gene expression distinguishes RDD from LCH and ECD. A, (Left) Individual normalized gene expression profiles of RDD, LCH, and ECD, respectively. (Right) Differential gene expression profiles of LCH vs. RDD, ECD vs. RDD, and LCH vs. ECD, respectively. Genes upregulated in each diagnosis are color-coded as indicated to the right. B and C, Gene set enrichment analysis showing upregulation of B cell genes (NES = 2.83, Padj = 5.39 × 10−8) and IL27 pathway genes (NES = 2.42, Padj = 1.75 × 10−4) in RDD and resting dendritic cell genes (NES = −2.14, Padj = 4.10 × 10−7) and HNF3A pathway genes (NES = −1.91, Padj = 7.59 × 10−4) in LCH. P values are adjusted by Benjamini–Hochberg correction. D, Each gene in the minimal marker panel exhibits significantly different expression in RDD (N = 23) compared with both LCH (N = 19) and ECD (N = 4). Shown are the mean and SE of log2-normalized expression scores. **, P < 0.01; ***, P < 0.001 by Mann–Whitney U test. E, Receiver operating characteristic (ROC) curve of the 5-gene classifier in distinguishing RDD (n = 23) from non-RDD (LCH and ECD, n = 19) cases. AUROC = 100%. F, Confusion matrix showing 100% accuracy of the 5-gene classifier in distinguishing RDD from non-RDD cases.


1 October 2026 in Cancer Research Communications
Verified
Journal Article
Open access
SYSheren Younes
Sheren Younes
FCFadzai Chinyengetere
Fadzai Chinyengetere
VRVeronica Russell
Veronica Russell
DTDevang Thakkar
Devang Thakkar
EMEmily F. Mason
Emily F. Mason
YNYasodha Natkunam
Yasodha Natkunam
Rosai–Dorfman disease (RDD) is a rare histiocytic disorder characterized by the accumulation of large histiocytes in nodal and/or extranodal sites. The underlying biology of RDD and factors that distinguish it from other histiocyte disorders are poorly understood. To better understand the disease biology, we employed whole-transcriptome RNA sequencing (RNA-seq) to study the gene expression profiles of RDD as part of the Atlas of Blood Cancer Genomes (ABCG) initiative. Gene expression profiles of RDD (N = 23) were then compared with two other histiocytoses [Langerhans cell histiocytosis (LCH; N = 15) and Erdheim–Chester disease (ECD; N = 4)], which are most often considered in the clinicopathologic differential diagnosis of RDD. We found that gene expression levels by RNA-seq correlated well with known immunohistochemistry results for diagnostic markers for all three diseases, highlighting the ability to use RNA-based approaches for the diagnosis of these tumors. RDD samples showed enrichment of gene sets related to B cells and the IL27 pathway. In contrast, LCH showed enrichment of gene sets related to resting dendritic cells and the HNF3A pathway. We found significant differences in the composition of the microenvironment, with an enrichment of memory B cells, plasma cells, and CD8 T cells in the RDD microenvironment and enrichment of dendritic cells in the LCH microenvironment. In summary, our study demonstrates unique gene expression signatures in RDD that show overlap as well as distinctive patterns from LCH or ECD. These novel gene expression signatures encompass pathways that could potentially contribute to the pathogenesis and targeted treatment of this rare histiocytic entity. Significance: To our knowledge, this study is the first to report that protein expression of markers used in the immunohistochemical diagnosis of RDD and other histiocytoses correlates well with gene expression. This finding indicates that RNA-based methods can be used in the clinical diagnosis of RDD. We also demonstrate that RDD shows a unique tumor microenvironment that is rich in immune cells, including B cells, plasma cells, and CD8+ T cells.